A Review and Look to the Future: BTKi in CLL and MCL
A Year in Review and a Look to the Future: BTKi in CLL and MCL

Released: November 20, 2023

Ana Marin-Niebla
Ana Marin-Niebla, MD, PhD
Stephan Stilgenbauer
Stephan Stilgenbauer, MD

Activity

Progress
1
Course Completed

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of:

  • SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
  • TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL
  • ZUMA-2: Brexucabtagene Autoleucel in R/R MCL
  • BRUIN: Pirtobrutinib for Previously Treated MCL
  • GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL
  • FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL
  • ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL
  • ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL
  • BRUIN: Pirtobrutinib for Previously Treated CLL